Please try another search
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Name | Age | Since | Title |
---|---|---|---|
Harpreet Singh | 48 | 2019 | CEO, MD, Member of Management Board & Executive Director |
Michael G. Atieh | 70 | 2020 | Independent Non-Executive Director |
Paul Rutherford Carter | 62 | 2020 | Independent Non-Executive Director |
Crystal L. Mackall | - | 2020 | Co-Chair of the Scientific Advisory Board |
Patrick Hwu | - | 2021 | Co-Chair of the Scientific Advisory Board |
Heather L. Mason | 61 | 2020 | Independent Vice Chair of the Board of Directors |
Peter Alan Chambré | 67 | 2012 | Non-Executive Chairman |
Roland Kontermann | - | 2020 | Member of Scientific Advisory Board |
Dirk Busch | - | 2021 | Member of Scientific Advisory Board |
Gwendolyn K. Binder | 48 | 2020 | Member of Scientific Advisory Board |
Adam Leo Stone | 43 | 2020 | Independent Non-Executive Director |
Hidde L. Ploegh | - | 2020 | Member of Scientific Advisory Board |
Cassian Yee | - | - | Member of Scientific Advisory Board |
Eliot Richard Forster | 57 | 2020 | Independent Non-Executive Director |
Mathias Hothum | 56 | 2023 | Non-Executive Director |
Anne Kerber | - | 2023 | Member of Scientific Advisory board |
Hans-Georg Rammensee | - | 2000 | Co-Founder & Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review